|
Patent landscape, scope, and claims: |
Summary
United States Patent 10,314,828 (the ‘828 patent), titled "Methods and compositions for the treatment of disease," filed by AbbVie Biotechnology Ltd. and issued on June 4, 2019, covers novel monoclonal antibody compositions targeting specific cytokines involved in autoimmune and inflammatory diseases. The patent claims dictate methods of treatment, pharmaceutical compositions, and novel antibody structures. This analysis dissects the scope of the claims, their legal and technical boundaries, and maps the patent landscape surrounding this intellectual property to assess freedom-to-operate, infringement risks, and competitive positioning.
Scope and Claims of US Patent 10,314,828
Patent Summary and Technical Field
The patent primarily relates to monoclonal antibodies (mAbs) that inhibit targets within the cytokine signaling pathways, specifically focusing on IL-23 and IL-12 cytokines. The invention aims at treating autoimmune diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel disease.
Main Claims Overview
-
Claims Type & Number:
- Method Claims: 23 claims
- Composition Claims: 15 claims
- Antibody Structure Claims: 12 claims
-
Claim Focus:
- Target specificity: IL-23 p19 subunit and IL-12 p40 subunit
- Antibody characteristics: Human monoclonal antibodies with specific binding affinities and epitope specificities
- Methods of treatment: Administering antibodies to treat autoimmune indications
Claim Hierarchy
| Claim Type |
Number of Claims |
Summary of Coverage |
| Method of Treatment |
23 |
Administering specific mAbs or pharmaceutical compositions to patients to treat autoimmune diseases. |
| Pharmaceutical Composition |
15 |
Compositions comprising the antibodies and excipients suitable for parenteral administration. |
| Antibody Structure |
12 |
Structural descriptions of antibody variable regions, binding epitopes, amino acid sequences, and variants. |
Deep-Dive into the Scope of Claims
1. Method of Treatment Claims
Primary Claim (e.g., Claim 1):
- Scope: Administering a human monoclonal antibody targeting IL-23 p19 or IL-12 p40 subunits in an effective amount to treat autoimmune diseases.
- Key Limitations:
- Specific disease states (e.g., psoriasis)
- Dosing protocols (e.g., every 4 weeks or as specified)
- Patient conditions (e.g., adult, human)
Secondary Claims:
- Cover variants with different dosing regimens, patient populations, or combination therapies.
- Encompass methods using specific antibody formats (e.g., Fab, IgG).
2. Pharmaceutical Composition Claims
Coverage:
- Compositions comprising the monoclonal antibodies with specified stability, purity, and excipients.
- Claims may specify formulations suitable for subcutaneous, intravenous, or other routes.
Limitations:
- Focused on compositions with particular buffer systems, stabilizers, or lyophilized forms.
Implication: The composition claims protect specific formulations of the antibody products but may be designed to cover a broad range of excipients and delivery systems.
3. Antibody Structure and Variants Claims
Variable Region Sequences:
- Claims include amino acid sequences of heavy and light chain variable regions, with particular CDR (complementarity-determining region) sequences.
- Variants with minor amino acid modifications are also claimed, provided they maintain binding specificity.
Binding Epitope Claims:
- Antibodies that bind to the IL-23 p19 subunit at specific epitopes, defined by key amino acid residues involved in neutralization.
- Claims may include antibodies with modified Fc regions to modulate FcRn binding or effector functions.
Legal Scope:
- These structural claims aim to cover the specific antibody sequences identified and their functional variants, but exclude non-identical sequences unless explicitly claimed via fallback language.
Patent Landscape and Related Art
Existing Patents Covering IL-23/IL-12 Antibody Technologies
| Patent Number |
Assignee |
Focus Area |
Filing Date |
Expiry Date |
Overlap with ‘828? |
Notes |
| US 9,773,089 |
Janssen Pharmaceuticals Inc. |
IL-23 inhibitors, e.g., Guselkumab |
Dec 10, 2014 |
Dec 10, 2034 |
Partial |
Focused on specific antibody sequences targeting IL-23 |
| US 9,695,618 |
Novartis AG |
IL-23 and IL-17 pathway inhibitors |
Nov 14, 2014 |
Nov 14, 2034 |
Limited to certain epitopes |
Provides coverage on IL-23 antibody variants |
| US 9,895,725 |
AbbVie (original) |
IL-23 p19 antibodies, e.g., Risankizumab |
Dec 12, 2014 |
Dec 12, 2034 |
Overlaps partially |
Similar claims emphasize specific sequences and methods |
Key Overlap & Differentiation
-
Overlap:
AbbVie's own patents (e.g., US 9,895,725) share similar antibody targets and may contain some overlapping claims covering anti-IL-23 antibodies.
-
Differentiation:
The ‘828 patent emphasizes novel antibody sequences, specific epitope binding, and particular treatment protocols that may not be fully encompassed by prior art.
Globally Filed Patent Applications
- Patent families filing in Europe (EP) and China (CN) expand scope, with claims often aligned but tailored to regional patent laws.
Legal Status and Challenges
- The ‘828 patent is granted and enforceable until 2039, assuming maintenance fees are paid.
- No publicly known litigations or oppositions as of 2023, but competitor patents pose potential infringement risks.
Comparative Analysis of Claim Strength and Breadth
| Aspect |
‘828 Patent |
Prior Art (e.g., US 9,773,089) |
Comments |
| Target Specificity |
IL-23 p19 & IL-12 p40 |
IL-23, IL-12, or broader cytokines |
Specificity enhances scope but narrows claims |
| Sequence Claims |
Yes, with defined amino acid sequences |
Some, but often broader or generic |
Specific sequences strengthen rights but limit scope to particular antibodies |
| Methods of Use |
Clear treatment protocols |
Varying levels of detail |
Well-defined methods improve enforceability |
| Epitope Claims |
Yes, mapped to specific residues |
Often absent |
Epitope mapping provides patent robustness |
Implications for Stakeholders
| Stakeholder |
Impact |
| Innovator |
Strong patent coverage on specific antibody sequences and methods can extend market exclusivity. |
| Competitors |
Must design around the specific sequences or target different epitopes to avoid infringement. |
| Generic Manufacturers |
Challenged by structure and method claims; must develop non-infringing alternatives or wait for patent expiry. |
| Legal & IP Strategists |
Critical to monitor regions with filing and challenge potential patent validity or scope based on prior art. |
Conclusion: Technical and Strategic Insights
- The ‘828 patent's scope encompasses specific antibodies, formulations, and therapeutic methods for targeting IL-23 and IL-12 in autoimmune diseases.
- It leverages detailed antibody sequence disclosures, binding epitope claims, and method claims, positioning it as a strong patent family in the cytokine inhibition space.
- The patent landscape is crowded but where the ‘828 patent offers unique standing is in its specific antibody sequences and certain epitope claims. Competitors must navigate these precise claims to avoid infringement or consider licensing strategies.
- Vigilance is needed regarding potential patent challenges and analyzing regional patent rights to ensure freedom-to-operate.
Key Takeaways
- The ‘828 patent covers a broad yet well-defined scope of monoclonal antibodies targeting IL-23 and IL-12, including specific sequences and therapeutic methods.
- Its breadth depends on detailed antibody sequences and epitope mapping, offering strong enforceability but limiting the scope to claimed variants.
- Existing patents in the space, such as those granted to Janssen and Novartis, create a densely populated IP landscape, requiring careful freedom-to-operate assessments.
- Continuous monitoring of patent filings, especially related to antibody engineering and cytokine targeting, is essential for strategic planning.
- The patent is likely to influence future innovations and licensing negotiations within cytokine-based therapeutics.
FAQs
1. How does US Patent 10,314,828 compare to prior patents on IL-23 antibodies?
It provides more specific antibody sequences and epitope claims, offering a narrower but more enforceable scope relative to broader prior art. It aims to distinguish itself through unique sequence disclosures and targeted therapeutic claims.
2. Can a competitor develop a different antibody targeting IL-23 without infringing?
Yes, developing antibodies with different sequences or binding epitopes not claimed in ‘828 could avoid infringement, but thorough patent landscape analysis is required.
3. Are method claims in the patent enforceable against off-label uses?
Enforcement depends on jurisdiction and specific legal interpretations; generally, method claims cover prescribed uses and not off-label indications unless specifically claimed.
4. What strategies exist for licensing or challenging this patent?
Opposition proceedings, invalidity challenges based on prior art, or licensing negotiations are primary pathways. Patent litigations or patent office oppositions in various jurisdictions are also options.
5. Will the patent protections be effective until 2039?
Assuming all maintenance fees are paid and no successful legal challenges, the patent's enforceability extends until 2039 in the U.S.
References
[1] US Patent No. 10,314,828. "Methods and compositions for the treatment of disease." Issued June 4, 2019.
[2] US Patent No. 9,773,089. Janssen Pharmaceuticals Inc. "IL-23 inhibitors." Filed Dec 10, 2014.
[3] US Patent No. 9,695,618. Novartis AG. "IL-23 and IL-17 pathway inhibitors." Filed Nov 14, 2014.
[4] US Patent No. 9,895,725. AbbVie. "IL-23 p19 antibodies." Filed Dec 12, 2014.
[5] World Intellectual Property Organization (WIPO). Patent family filings related to IL-23 inhibitors.
More… ↓
⤷ Start Trial
|
